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A reliable tool for
examining the
processes thatunderpin hepatic
steatosisThis protocol describes the production of hepatocyte-like cells (HLCs) from human pluripotent
stem cells and how to induce hepatic steatosis, a condition characterized by intracellular lipid
accumulation. Following differentiation to an HLC phenotype, intracellular lipid accumulation is
induced with a steatosis induction cocktail, allowing the user to examine the cellular processes
that underpin hepatic steatosis. Furthermore, the renewable nature of our system, on a defined
genetic background, permits in-depth mechanistic analysis, which may facilitate therapeutic
target identification in the future.Sinton et al., STAR Protocols 2,
100493
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https://doi.org/10.1016/j.xpro.2021.100493SUMMARY
This protocol describes the production of hepatocyte-like cells (HLCs) from hu-
man pluripotent stem cells and how to induce hepatic steatosis, a condition char-
acterized by intracellular lipid accumulation. Following differentiation to an HLC
phenotype, intracellular lipid accumulation is induced with a steatosis induction
cocktail, allowing the user to examine the cellular processes that underpin hepat-
ic steatosis. Furthermore, the renewable nature of our system, on a defined ge-
netic background, permits in-depth mechanistic analysis, which may facilitate
therapeutic target identification in the future.
For complete details on the use and execution of this protocol, please refer to
Sinton et al. (2021).BEFORE YOU BEGIN
Coat culture plates with Laminin-521
Timing: 30 min
1. Thaw a 100 mg/mL stock of Laminin-521 (LN-521) for 16–18 h at 4C.
2. Thawed LN-521 should be diluted in ice-cold 1X DPBS (containing Ca2+ andMg2+), to generate a
5 mg/mL stock solution.
3. Add sufficient LN-521 to each well of a culture plate to coat. For a 6-well plate, add 1 mL of LN-
521 to each well. For a 10 cm petri dish, add 5 mL of LN-521 to coat the plate.
4. After coating, incubate the plates at 4C for 16–18 h on a flat surface. Alternatively, plates can be
incubated in a 37C/5% CO2 cell culture incubator for 2 h.
5. Plates should be sealed to prevent evaporation of LN-521, stored at 4C, and used within
2 weeks.
6. Prior to use, allow the plates to equilibrate to 18C–25C by placing on a flat surface for 2 h. Alter-
natively, warm the plates in a 37C/5% CO2 cell culture incubator for 30 min.
CRITICAL: It is critical that the LN-521 does not evaporate. Seal plates with parafilm toavoid evaporation. Following incubation, LN-521 coating, tip plates 45 and observe the
growing surface. If the growing surface plastic can be seen when tipping, then coating
has not been successful and must be repeated. If repeated coating is necessary, the addi-
tion of an extra 1 mL DPBS can reduce the chance of this occurring.STAR Protocols 2, 100493, June 18, 2021 ª 2021 The Author(s).
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESS ProtocolPreparation of differentiation media, growth factors, and steatosis induction cocktail
Timing: 4 h
7. Stem cell media2
a. Add 100 ml mTeSR1 5X supplement to the 400 ml mTeSR1 basal medium. Store for up to
1 month at 4C.8. Differentiation mediaa. To prepare endoderm differentiation medium, add 1% penicillin streptomycin and 1X B27
supplement to 500 mL RPMI 1640 medium. Store for up to 1 month at 4C.
b. To prepare hepatic progenitor differentiation medium, mix 400 ml knockout (KO)-DMEM,
100 ml KOSR Serum Replacement, 1% penicillin/streptomycin, 1% DMSO, 1% non-essential
amino acids, 0.5% Glutamax and 0.2% b-mercaptoethanol. Store for up to 1 month at 4vC.
This media formulation was previously optimized (Wang et al., 2017).
c. To prepare hepatocyte maturation media, add 1% Glutamax, 1% penicillin streptomycin,
20 ng/mL hepatocyte growth factor, 10 ng/mL oncostatin M and 10 mM hydrocortisone
21-hemisuccinate sodium salt to HepatoZYME medium. Store for up to 1 month at 4C.
9. Preparation of growth factors and other reagentsa. Prepare a 1,000X stock of human activin A, by dissolving the lyophilized protein in sterile
0.2% bovine serum albumin (BSA; mixed with DPBS), giving a final concentration of
100 mg/mL. Prepare 30 mL aliquots and store at 20C. Use at a 1:1000 dilution.
b. Prepare a 1,000X stock of Wnt3A. Dissolve lyophilized mouse Wnt3A protein in sterile 0.2%
BSA/DPBS, to a final concentration of 10 mg/mL. Prepare 30 mL aliquots and store at 20C.
Use at a 1:200 dilution.
c. Prepare hydrocortisone 21-hemisuccinate sodium salt solution (HCC) by dissolving HCC in
DPBS to a final concentration of 10 mM. Sterile filter the solution using a 22 mm filter and store
in 5 mL aliquots at 20C. Use at a 1:100 dilution.
d. Prepare a 1,000X stock of human hepatocyte growth factor. Dissolve lyophilized HGF in ster-
ile BSA/DPBS, to a final concentration of 10 mg/mL. Prepare 30 mL aliquots and store at
20C. Use at a 1:1000 dilution.
e. Prepare a 1,000X stock of oncostatin M. Dissolve lyophilized Oncostatin M (OSM) in sterile
BSA/DPBS, to a final concentration of 20 mg/mL. Prepare 30 mL aliquots and store at
20C. Use at a 1:1000 dilution.
f. Prepare a 1,000x stock solution of Rho-associated kinase (ROCK) inhibitor Y-27632. Dissolve
in sterile 0.2% BSA/DPBS to a final concentration of 10 mM. Prepare 10 mL aliquots and store
at 20C. Use at a 1:1000 dilution.
10. Prepare components of steatosis induction cocktail 24 h prior to use.a. Dissolve sodium L lactate in DPBS to a concentration of 1 M. Sterile filter the solution with a
22 mm filter. Store in 1 mL aliquots at 20C for up to 1 week.
b. Dissolve sodium pyruvate in DPBS to a concentration of 100 mM. Sterile filter the solution
with a 22 mm filter. Store in 1 mL aliquots at 20C for up to 1 week.
c. Prepare octanoic acid to a 100 mM concentration in sterile water. Add lyophilized octanoic
acid to sterile deionized water. Adjust pH to 7.0 – 7.9 by addition of 4 M NaOH solution with
constant stirring. When solution becomes clear, store in 1 mL aliquots at 20C for up to
1 week.
CRITICAL: Steatosis induction cocktail compounds stored for longer than 1 week becomedecreasingly effective and should be discarded.11. Prepare steatosis induction cocktail on the day of use.a. Add lactate, pyruvate, and octanoic acid to HepatoZYME media, to a final concentration of
10mM, 1mM and 2mM, respectively. Sterile filter the solution prior to use.STAR Protocols 2, 100493, June 18, 2021
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Chemicals, peptides, and recombinant proteins
Activin A PeproTech Cat#120-14E
B-Mercaptoethanol Gibco Cat#31350-010




Bovine serum albumin Sigma-Aldrich Cat#A2058
13C3-Lactate CK Isotopes Cat#CLM-1579-05
Dimethyl sulfoxide Thermo Fisher Cat#D5879
DPBS (without Ca2+/Mg2+) Thermo Fisher Cat#14190144
GlutaMAX Supplement Thermo Fisher Cat#35050-038
HCS CellMask Red Invitrogen Cat#H32712
Hepatocyte growth factor PeproTech Cat#100-39
Human recombinant laminin 521 BioLamina Cat#LN521-02
Hydrocortisone 21-hemisuccinate sodium salt Sigma-Aldrich Cat#H4881-1G
MEM Non-Essential Amino Acids Solution (100X) Gibco Cat#11140-035
Multidrop Combi Reagent Dispenser Thermo Fisher Cat#5840300
NucBlue Live ReadyProbes Reagent Molecular Probes Cat#R37605
Octanoic acid Sigma-Aldrich Cat#C2875
Oncostatin M PeproTech Cat#300-10
Paraformaldehyde (4% wt/vol) Electron Microscopy
Sciences
Cat#15710-S
Penicillin-streptomycin (10,000 U/mL) Gibco Cat#15140-122
QIAzol QIAGEN Cat#79306
Rho-associated kinase (ROCK) inhibitor Y27632 Sigma-Aldrich Cat#Y0503-1MG
RIPA Lysis and Extraction Buffer Thermo Scientific Cat#89900
Sodium L lactate Sigma-Aldrich Cat#L7022
Sodium pyruvate Sigma-Aldrich Cat#P5280
Triton X-100 Sigma-Aldrich Cat#T8787
Universal ProbeLibrary – probe #7 (for use
with ALB oligonucleotides)
Roche Cat#4685059001
Universal ProbeLibrary – probe #27 (for use
with HNF4A oligonucleotides)
Roche Cat#4687574001
Universal ProbeLibrary – probe #69 (for use
with NANOG oligonucleotides)
Roche Cat#4688678001
Universal ProbeLibrary – probe #72 (for use
with PLIN2 oligonucleotides)
Roche Cat#4688953001
Universal ProbeLibrary – probe #1 (for use
with PLIN4 oligonucleotides)
Roche Cat#4684974001
Universal ProbeLibrary – probe #3 (for use
with PLIN5 oligonucleotides)
Roche Cat#4685008001




P450-Glo CYP3A4 Assay and Screening System Promega Cat#V8801
Experimental models: cell lines
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96 Well Cell Culture Microplates, mClear Greiner Bio-One Cat#655087
DPBS with Calcium and Magnesium Thermo Fisher Cat#14040133
Gentle cell dissociation reagent STEMCELL Technologies Cat#7174
GloMax explorer multiplex plate reader Promega Cat#GM3500
HepatoZYME-SFM Gibco Cat#17705-021
High-Capacity cDNA Reverse Transcriptase Kit Applied Biosystems Cat#4368814
Knockout DMEM Gibco Cat#
10829-018
KnockOut Serum Replacement (KO-SR) Gibco Cat#10828-028
LightCycler 480 Roche
Luna Universal Probe qPCR Master Mix New England Biolabs Cat#M3004S
Monarch Total RNA Miniprep Kit New England Biolabs Cat#T2010
mTeSR1 medium STEMCELL Technologies Cat#85850
Operetta CLS High-Content Analysis System PerkinElmer Part# HH16000000
PCR Plate, 384-well, standard Thermo Scientific Cat#AB1384
Pierce BCA Protein Assay Kit Thermo Fisher Cat#23225
Primer Thermal Cycler Techne N/A
RPMI 1640 Gibco Cat#11875-093
TURBO DNA-free Kit Ambion Cat#
White plates for CYP assays Greiner Bio-One Cat#655075
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Passaging human pluripotent stem cells (hPSCs) in preparation for differentiation
Timing: 1 day
This step describes the preparation of hPSCs for differentiation to hepatocyte-like cells (HLCs)
(Figure 1). The protocol requires that hPSCs are at a confluence of 75%–80%. For passaging, hPSCs
must be in a single cell suspension. This protocol was adapted from (Lyall et al., 2018; Meseguer-Ri-
polles et al., 2018; Wang et al., 2017).
1. When hPSCs are at 75%–80% confluence, aspirate media.
2. Wash each well with 18C–25C 1X DPBS (without Ca2+/Mg2+) and then aspirate.
3. Add 1 mL of Gentle Cell Dissociation Reagent (STEMCELL Technologies) to each well and incu-
bate cells at 37C/5%CO2, for 5–8min, to promote dissociation of cells from the growing surface.
4. Whilst cells are dissociating, prepare the Laminin-521-coated plates. Carefully aspirate Laminin-
521 from the well, without disturbing the coating on the growing surface.4 STAR Protocols 2, 100493, June 18, 2021
Figure 1. Schematic of differentiation processes and treatments required at each timepoint
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OPEN ACCESSProtocolCRITICAL: Do not allow the Laminin-521 to dry out at any point. If the Laminin-521 poolsand exposes a dry plastic growing surface, then coating has not been successful and must
be repeated prior to starting the differentiation process.5. Immediately after aspirating, add 1 mL of supplemented mTeSR1, pre-warmed to 37C, con-
taining 10 mM Rho-associated kinase (ROCK) inhibitor Y-27632 to each well of a 6-well plate.
This is half of the media that will be added to each well.
Note: ROCK inhibitor Y-27632 is used to enhance hPSC attachment and survival in single cell
suspensions.
6. Incubate the LN-521 coated plates, with ROCK-supplemented media, at 37C/5% CO2 until the
hPSCs are dissociated and ready for plating.
7. To determine whether hPSCs have formed a single cell suspension, observe the plates under a
standard light microscope. If the cells are not ready, increase the incubation step, to a maximum
of 10min. Cells will start to look round when their edges are detaching from the growing surface.
8. Aspirate the Gentle Cell Dissociation Reagent and immediately add 1 mL of pre-warmed sup-
plemented mTeSR1 with 10 mM ROCK inhibitor Y-27632 to each well.
9. Detach cells from the growing surface using a cell scraper.
10. Collect the media, containing suspended hPSCs, into a 15 mL Falcon tube and centrifuge at
200 3 g for 5 min, at 18C–25C.
11. Aspirate the media without disturbing the cell pellet and then tap the tube to ensure that there
are no clumps.
12. To the Falcon tube, add 10 mL of supplemented mTeSR1with 10 mM ROCK inhibitor Y-27632.
Slowly pipette up and down to resuspend the cell pellet. Count the cells using an automatic cell
counter and use Trypan Blue to exclude dead cells. Count cells three times and calculate the
mean number of cells.
Note: Manual counting is not recommended as it introduces user-to-user variation
13. Seed the cells at a density of 5.0 3 104 cells per cm2 growing surface. Seeding density may
require optimization for different well sizes or shapes.
14. Place the plate on a flat surface and gently shake the plate up and down, then left to right, for 10
times each.
15. Incubate the hPSCs at 37C/5% CO2 for 24 h before starting the differentiation protocol.Hepatocyte-like cell differentiation
Timing: 17 days
This protocol describes how to differentiate hPSCs to hepatocyte-like cells (HLCs) and generates ho-
mogeneous populations. This protocol below was previously described (Wang et al., 2017).STAR Protocols 2, 100493, June 18, 2021 5
Figure 2. Differentiation of H9 cells leads to associated changes in cell morphology
Representative images of cell morphology during the differentiation process.
(A) H9 cells approximately 24 h after seeding onto Laminin-521 coated plates and reaching 40% confluence.
(B) H9 cells on day 3, at the endoderm stage.
(C) H9 cells on day 9, following induction of hepatoblast differentiation.
(D) H9 cells at day 17, following maturation to HLCs. Scale bar, 25 mm. Adapted from Sinton et al 2021, iScience,
https://doi.org/10.1016/j.isci.2020.101931
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OPEN ACCESS Protocol16. Once hPSCs reach 40% confluence (Figure 2A), normally 1 day after seeding, begin the differ-
entiation process. This timing is variable and it can take between 18 and 24 h for cells to reach
40% confluence if cell counts are not accurate.
17. Aspirate the supplemented mTeSR1 and replace with 2 mL RPMI 1640 supplemented with
100 ng/mL Activin A and 50 ng/mL Wnt3A. Incubate the cells at 37C/5% CO2 and refresh
the media every 24 h for 3 days.
18. On day 3, H9 cells should achieve an endodermal morphology (Figure 2B). Aspirate endoderm
differentiation medium and replace with hepatic progenitor differentiation medium. Incubate
the cells at 37C/5% CO2 and refresh the media every 48 h for 5 days.
19. On day 9, H9 cells should achieve a hepatoblast morphology (Figure 2C). Aspirate the hepatic
progenitor differentiation medium and replace with hepatocyte maturation medium, supple-
mented with 10 ng/mL hepatocyte growth factor and 20 ng/mL oncostatin M. Incubate the cells
at 37C/5% CO2 and refresh the media every 48 h for 9 days.
20. On day 17, H9 cells should achieve a hepatocyte morphology (Figure 2D). HLCs are nowmature
and ready to be used in downstream assays.
21. To determine that cells are functioning as mature hepatocytes, measure CYP3A4 activity on day
17, using the P450-Glo assay (Promega), as per the manufacturer’s instructions (https://www.
promega.co.uk/products/cell-health-assays/adme-assays/
p450-glo-cyp3a4-assay-and-screening-system/?catNum=V9001#protocols). Results should be
normalized to protein content of the well analyzed. Measure protein using the Pierce BCA Pro-
tein Assay Kit as per the manufacturer’s instructions (https://www.thermofisher.com/order/
catalog/product/23225#/23225).
Note: At days 0, 3, 9 and 17, collect cells to measure mRNA of the pluripotency marker
NANOG, and the hepatocyte markers HNF4A and ALB (Figure 3). This enables the tracking
of the changing cell phenotype throughout the differentiation process.6 STAR Protocols 2, 100493, June 18, 2021
Figure 3. Differentiation process leads to loss of pluripotency and gain of hepatocyte maturation markers
Temporal expression of pluripotency marker (NANOG) and hepatocyte markers (ALB and HNF4A) during
differentiation of hPSCs to HLCs (data are expressed as meanG SD; n = 8). Adapted from Sinton et al 2021, iScience,
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OPEN ACCESSProtocolhttps://doi.org/10.1016/j.isci.2020.101931Induction of and verification of steatosis
Timing: [2 days]
This step leads to the accumulation of intracellular lipids within the HLCs, and mimics human hepatic
steatosis. This protocol was adapted from (Lyall et al., 2018).
22. On day 17 of HLC differentiation, aspirate the hepatocyte maturation media. Replace this with
hepatocyte maturation media supplemented with sodium L-lactate (10 mM), sodium pyruvate
(1 mM) and octanoic acid (2 mM). Incubate the cells at 37C/5% CO2 for 48 h.
Note: Following induction of steatosis, cells from a single well can be used for either imaging
or mRNA collection, but the same well cannot be used for both purposes.
23. For microscopy analysis of lipid accumulation, aspirate cell media and replace with 4% (weight/
volume) paraformaldehyde in DPBS. Incubate at 18C–25C for 15 min.
24. Aspirate the paraformaldehyde and replace with DPBS containing 0.1% Triton X-100 for 15 min
at 18C–25C, to permeabilize the cells.
25. Stain the cells with 2 mL/10 mL HCS CellMask Red, 2 drops/mL NucBlue Live ReadyProbes
Reagent, and 1:1000 BODIPY 493/503. Following incubation with these stains, incubate in
the dark, at 18C–25C, for 30 min.
26. Following staining, use fluorescence microscopy to assess intracellular lipid accumulation. For
this purpose, we used an Operetta CLS High-Content Analysis System.
27. To further confirm lipid accumulation, mRNA of markers for lipid droplets, perilipin 2 (PLIN2),
PLIN4 and PLIN5 can be measured.
28. To purifymRNA fromHLCs, wash cells twice withDPBS. Incubate the cells with 1mLQIAzol for 5min
at 18C–25C. Then purify mRNA using the Monarch Total RNA Miniprep Kit as per the manufac-
turer’s instructions (https://www.neb.uk.com/products/neb-catalogue/nucleic-acid-purification/
monarch-lt;sup-gt;-amp;reg;-lt;-sup-gt;-total-rna-miniprep-kit).
29. Reverse transcribe RNA using the TURBO DNA-free Kit according to the manufacturer’s in-
structions (https://www.thermofisher.com/order/catalog/product/AM1907#/AM1907).
30. Measure mRNA using the Luna Universal Probe qPCR Master Mix, as per the manufacturer’s
instructions (https://international.neb.com/products/m3004-luna-universal-probe-qpcr-master-mix#
Protocols,%20Manuals%20&%20Usage) and the conditions outlined in Table 1.STAR Protocols 2, 100493, June 18, 2021 7
Table 1. Cycling conditions for qPCR measurements of mRNA
qPCR cycling conditions
Steps Temperature Time Cycles
Preincubate 95C 5 min 1
Denaturation 95C 10 sec 40 cycles
Annealing/extension 60C 30 sec
Cool 40C 30 sec 1




ProtocolNote:Measurements of lipid marker mRNA should be used in tandemwith microscopy to give
confidence that steatosis is developing in HLCs treated with lactate, pyruvate, and octanoic
acid.EXPECTED OUTCOMES
This protocol generates stem cell-derived hepatocyte-like cells, which are phenotypically similar to
mature human hepatocytes. Figure 3 demonstrates that following differentiation, cells acquire
expression of markers typically associated with hepatocytes, which they lack in the pluripotent state.
HNF4A activity is understood to be crucial for hepatic progenitor specification (Wang et al., 2019)
and, therefore, it is essential to confirm that cells are expressing this marker prior to hepatocyte
maturation. Figure 4 highlights that these cells also acquire functional activity that is representative
of cytochrome activity associated with primary hepatocytes. Following treatment with lactate, pyru-
vate, and octanoic acid, HLCs accumulate greater volumes of intracellular lipid, as demonstrated by
BODIPY staining in Figure 5. This is accompanied by an increase in expression of markers associated
with lipid droplet biogenesis – PLIN2, PLIN4 and PLIN5, highlighted in Figure 6. Recently developed
in silico tools enable mathematical modeling of oxygen gradients within liver tissue, providing
insight into how these gradients will impact on cell phenotype (Leedale et al., 2021). This platform
can be scaled and provides an excellent tool to study liver biology and disease (Lucendo-Villarin
et al., 2020a, 2020b; Sinton et al., 2021).LIMITATIONS
Although HLCs are morphologically and functionally similar to hepatocytes, they do not necessarily
recapitulate the entire transcriptome of human hepatocytes (Godoy et al., 2015). Whilst LPO-treated
HLCs express a substantial number of steatosis-related genes (Sinton et al., 2021), it is unclear how
expression patters are impacted by the lack of co-culture with other liver-resident cells, such asFigure 4. Maturation of HLCs is associated with functional
activity typically associated with human hepatocytes
Cytochrome P450 3A4 activity in HLCs following differentiation
with or without the lactate, pyruvate, octanoic acid (LPO) cocktail
(data are expressed as meanG SD; n = 8). Adapted from Sinton et
al 2021, iScience, https://doi.org/10.1016/j.isci.2020.101931
STAR Protocols 2, 100493, June 18, 2021
Figure 5. Treatment of HLCs with steatosis induction cocktail leads to intracellular lipid accumulation
Representative images of lipid accumulation in control (A) and LPO-treated (B) groups; 10x magnification. Hoechst
dye (NucBlue) and BODIPY were used to stain nuclei or neutral lipids, respectively. Adapted from Sinton et al 2021,
iScience, https://doi.org/10.1016/j.isci.2020.101931
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OPEN ACCESSProtocolendothelial, stellate or Kupffer cells, but this system still provides invaluable insights into the
response of hepatocytes to steatosis.TROUBLESHOOTING
Problem 1
Following coating of tissue culture plastic with Laminin-521, the coating does not fully cover the well,
exposing the growing surface.Potential solution
Coating of plates with Laminin-521 is vital prior to cell seeding. Check that the correct concentration
of Laminin-521 was used and that the plates were incubated for the correct length of time. Repeat
the coating process and if the problem persists, increase the volume of Laminin-521 in the well and
ensure that plates are being stored on a completely flat surface.Problem 2
Following seeding of H9s onto wells coated with Laminin-521, there are high levels of cells death,
leading to sparse seeding of the well.Potential solution
When preparing a single cell suspension of H9 cells, media must contain ROCK inhibitor Y-27632 to
prevent excessive cell death. Prior to addition of endoderm differentiation medium, H9 cells that are
seeded for differentiation should be incubated in mTeSR1 basal medium containing ROCK inhib-
itor Y-27632.Problem 3
When seeding single cells prior to differentiation, cells may not be distributed homogeneously,
leading to heterogeneous patterns of differentiation within the well. If this occurs, by day 9 of the
differentiation process, cells may not reach confluence and morphology will not appear consistent
across the well.Potential solution
Attachment of the pluripotent stem cells to Laminin-521-coated plates occurs rapidly. To ensure that
cells are distributed evenly across the growing surface of the well or plate, gently agitate the plate up
and down, and side-to-side, at least 10 times prior to transfer to the incubator.STAR Protocols 2, 100493, June 18, 2021 9
Figure 6. Accumulation of intracellular lipids in HLCs is associated with increased lipid droplet markers
Expression of PLIN2 (A), PLIN4 (B) and PLIN5 (C) was measured. For each group n = 3 biological replicates. Data were
analyzed using a two-tailed Student t-test and expressed as meanG SD. *p<0.05, ****p<0.0001. Adapted from Sinton
et al 2021, iScience, https://doi.org/10.1016/j.isci.2020.101931.
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Differentiation of H9 cells to the endoderm, hepatoblast or HLC specification are unsuccessful as
determined by qPCR analysis of pluripotency of hepatocyte markers.Potential solution
Check that the components of each differentiationmedia have been prepared to the correct concen-
tration and stored under the correct conditions.Problem 5
Induction of steatosis may be unsuccessful, as determined by BODIPY staining and
immunofluorescence.Potential solution
Components of the steatosis-induction cocktail have a limited shelf life. It is strongly recommended
that storage conditions are checked and that fresh solutions are prepared if cells are not developing
steatosis following 48 h of incubation with this cocktail.RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, David C. Hay (davehay@talktalk.net).Materials availability
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact.Data and code availability
Datasets will be made available upon request to the lead contact.ACKNOWLEDGMENTS
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